Takeda Continues Diversification By Hiring French COO From GSK
This article was originally published in The Pink Sheet Daily
GSK vaccines executive Christophe Weber will join Takeda as chief operating officer next spring and could be installed as the Japanese pharma’s next CEO a year later. Ironically, Weber negotiated a joint venture with Takeda competitor Daiichi Sankyo in 2012 to challenge Takeda’s primacy in the Japanese vaccines market.
You may also be interested in...
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
A workshop broadcast from White Oak was a shift from the fully virtual meetings held since the height of the COVID-19 pandemic and may be a step toward once again staging public events there.
With two weeks to go before hearing on whether the preterm birth prevention drug can stay on the market or be withdrawn, the lack of clarity on who will make the ultimate decision may stem from the lengthy duration of the dispute and multiple transitions within FDA’s senior leadership.